| MicroRNA-214 promotes myogenic differentiation by facilitating exit from mitosis via down-regulation of proto-oncogene N-ras. | None |
| proto-oncogene N-ras is an miR-214 target | None |
| Proto-oncogenic H-Ras, K-Ras, and N-Ras are involved in muscle differentiation via phosphatidylinositol 3-kinase. | None |
| phenotypic, cellular, and biochemical consequences of endogenous oncogenic Nras expression in hematopoietic cells | None |
| Hematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus. | None |
| In-vivo and in-vitro analysis of retroviral vectors carrying the N-ras oncogene. | None |
| The tumor transformation potential of endogenous oncogenic Nras is both dose- and cell type-dependent. | None |
| Tumorigenesis and male sterility in transgenic mice expressing a MMTV/N-ras oncogene. | None |
| Regulation of protein kinase C activity in neuronal differentiation induced by the N-ras oncogene in PC-12 cells. | None |
| Malignant transformation of human fibroblasts by a transfected N-ras oncogene. | None |
| Introduction of the activated N-ras oncogene into human fibroblasts by retroviral vector induces morphological transformation and tumorigenicity. | None |
| Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras. | None |
| N-ras 61 oncogene mutations in Hurthle cell tumors. | None |
| findings suggest a gradient model of oncogenic NRAS signaling in which the output is gated, resulting in the decoupling of discrete downstream biological phenotypes as a result of incomplete inhibition. | None |
| Dominant role of oncogene dosage and absence of tumor suppressor activity in Nras-driven hematopoietic transformation. | None |
| a single allele of oncogenic Nras(G12D) increases HSC proliferation but also increases reconstituting and self-renewal potential upon serial transplantation in irradiated mice, all prior to leukaemia initiation | None |
| Evaluation of N-ras oncogene anti-sense, sense and nonsense sequence methylphosphonate oligonucleotide analogues. | None |
| Oncogenicity of human N-ras oncogene and proto-oncogene introduced into retroviral vectors. | None |
| The prevalence of oncogenic RAS mutations was higher among Arab Asian children than in other countries. RAS mutations in AML were found to coexist with other genetic aberrations, particularly MLL rearrangement | None |
| Identification of resonances from an oncogenic activating locus of human N-RAS-encoded p21 protein using isotope-edited NMR. | None |